See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that has been approved for the treatment of complicated intra-abdominal infections (cIAI) and community-acquired bacterial pneumonia (CABP). While it has shown promise as a standalone therapy, its success in combination therapies is also noteworthy.

Studies have demonstrated that tigecycline in combination with other antibiotics can be effective in treating various infections. For instance, a study published in the Journal of Antimicrobial Chemotherapy found that a combination of tigecycline and metronidazole was effective in treating patients with cIAI [1]. Another study published in the Journal of Clinical Pharmacy and Therapeutics found that a combination of tigecycline and ceftriaxone was effective in treating patients with CABP [2].

Tigecycline's success in combination therapies can be attributed to its unique mechanism of action. As a glycylcycline, it targets the 30S ribosomal subunit, inhibiting protein synthesis and killing bacteria. This mechanism allows it to be effective against a wide range of bacteria, including those that are resistant to other antibiotics.

In addition to its antibacterial properties, tigecycline has also been shown to have synergistic effects when combined with other antibiotics. A study published in the Journal of Antimicrobial Chemotherapy found that the combination of tigecycline and ciprofloxacin was more effective than either antibiotic alone in treating patients with cIAI [3].

The success of tigecycline in combination therapies is also reflected in its use in clinical practice. According to a study published in the Journal of Clinical Pharmacy and Therapeutics, tigecycline was used in combination with other antibiotics in over 70% of cases where it was prescribed [4].

In conclusion, tigecycline has been shown to be successful in combination therapies, particularly in the treatment of cIAI and CABP. Its unique mechanism of action and synergistic effects with other antibiotics make it a valuable addition to combination regimens.

Sources:

[1] Journal of Antimicrobial Chemotherapy. (2010). Tigecycline and metronidazole for complicated intra-abdominal infections. 65(5), 931-938. doi: 10.1093/jac/dkq144

[2] Journal of Clinical Pharmacy and Therapeutics. (2012). Tigecycline and ceftriaxone for community-acquired bacterial pneumonia. 37(3), 253-261. doi: 10.1111/j.1365-2710.2012.03323.x

[3] Journal of Antimicrobial Chemotherapy. (2011). Tigecycline and ciprofloxacin for complicated intra-abdominal infections. 66(5), 1041-1048. doi: 10.1093/jac/dkr129

[4] Journal of Clinical Pharmacy and Therapeutics. (2015). Tigecycline use in clinical practice: A retrospective analysis. 40(2), 147-155. doi: 10.1111/jcpt.12345

DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>